CY1113243T1 - Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 - Google Patents
Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4Info
- Publication number
- CY1113243T1 CY1113243T1 CY20121100606T CY121100606T CY1113243T1 CY 1113243 T1 CY1113243 T1 CY 1113243T1 CY 20121100606 T CY20121100606 T CY 20121100606T CY 121100606 T CY121100606 T CY 121100606T CY 1113243 T1 CY1113243 T1 CY 1113243T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- methods
- ctla
- human
- infections
- Prior art date
Links
- 102000008203 CTLA-4 Antigen Human genes 0.000 title 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 title 1
- 229940045513 CTLA4 antagonist Drugs 0.000 title 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000043321 human CTLA4 Human genes 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει καινοτόμες ανθρώπινες αλληλουχίες αντισωμάτων κατά του ανθρώπινου CΤLΑ-4 και μεθόδους για τη θεραπευτική αγωγή ανθρώπινων ασθενειών, λοιμώξεων και άλλων καταστάσεων χρησιμοποιώντας τα αντισώματα αυτά.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37228402P | 2002-04-12 | 2002-04-12 | |
US38127402P | 2002-05-17 | 2002-05-17 | |
EP03728392A EP1503794B9 (en) | 2002-04-12 | 2003-04-11 | Methods of treatement using ctla-4 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113243T1 true CY1113243T1 (el) | 2016-04-13 |
Family
ID=29254482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100606T CY1113243T1 (el) | 2002-04-12 | 2012-07-06 | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 |
Country Status (19)
Country | Link |
---|---|
US (2) | US7452535B2 (el) |
EP (1) | EP1503794B9 (el) |
JP (1) | JP2005529873A (el) |
CN (1) | CN1652820A (el) |
AT (1) | ATE552849T1 (el) |
AU (2) | AU2003234736B2 (el) |
BR (1) | BR0309254A (el) |
CA (1) | CA2481207C (el) |
CY (1) | CY1113243T1 (el) |
DK (1) | DK1503794T3 (el) |
ES (1) | ES2384168T3 (el) |
HU (1) | HUS1200022I1 (el) |
IL (2) | IL164287A0 (el) |
MX (1) | MXPA04010013A (el) |
NZ (1) | NZ536420A (el) |
PT (1) | PT1503794E (el) |
SI (1) | SI1503794T1 (el) |
WO (1) | WO2003086459A1 (el) |
ZA (1) | ZA200408732B (el) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
EP1503794B9 (en) * | 2002-04-12 | 2012-09-19 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
WO2005092380A2 (en) * | 2004-03-26 | 2005-10-06 | Pfizer Products Inc | Uses of anti-ctla-4 antibodies |
PL1758610T3 (pl) * | 2004-05-20 | 2012-11-30 | Zymogenetics Inc | Sposoby leczenia raka z zastosowaniem IL-21 i terapii przeciwciałem monoklonalnym |
US20060057626A1 (en) * | 2004-09-03 | 2006-03-16 | Nichol Geoffrey M | Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy |
US20090252741A1 (en) * | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
US20080152655A1 (en) * | 2004-09-08 | 2008-06-26 | The Ohio State University Research Foundation | Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies |
US20060165687A1 (en) * | 2004-10-19 | 2006-07-27 | Duke University | Vaccine adjuvant |
US20080085261A1 (en) * | 2004-10-19 | 2008-04-10 | Haynes Barton F | Vaccine Adjuvant |
TW200700082A (en) * | 2005-03-23 | 2007-01-01 | Pfizer Prod Inc | Therapy of prostate cancer with ctla4 antibodies and hormonal therapy |
LT2397156T (lt) | 2005-06-08 | 2017-02-27 | Dana-Farber Cancer Institute, Inc. | Būdai ir kompozicijos, skirti nuolatinių infekcijų ir vėžio gydymui inhibuojant užprogramuotos ląstelės mirties-1 (pd-1) kelią |
NZ568016A (en) * | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
WO2010003057A2 (en) | 2008-07-03 | 2010-01-07 | Mayo Foundation For Medical Education And Research | Treating cancer |
US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
US9598491B2 (en) | 2008-11-28 | 2017-03-21 | Emory University | Methods for the treatment of infections and tumors |
EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
CN102481341B (zh) | 2009-02-23 | 2017-05-17 | 希托马克斯医疗有限公司 | 蛋白原及其使用方法 |
CA2763685A1 (en) * | 2009-05-29 | 2010-12-02 | The Board Of Regents Of The University Of Texas System | Peptoid ligands for isolation and treatment of autoimmune t-cells |
SI2769737T1 (sl) * | 2009-07-20 | 2017-06-30 | Bristol-Myers Squibb Company | Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
JP6240063B2 (ja) | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート, インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
WO2013142796A2 (en) * | 2012-03-23 | 2013-09-26 | Bristol-Myers Squibb Company | Methods of treatments using ctla4 antibodies |
US20150118244A1 (en) | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
CA2880117C (en) | 2012-07-27 | 2021-04-06 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
EP3967306A1 (en) | 2012-10-01 | 2022-03-16 | Mayo Foundation for Medical Education and Research | Cancer treatments |
US20150202291A1 (en) * | 2013-11-05 | 2015-07-23 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
EA201692458A1 (ru) | 2014-05-28 | 2017-06-30 | Агенус Инк. | Анти-gitr антитела и способы их применения |
KR20170020371A (ko) | 2014-06-16 | 2017-02-22 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
IL251669B2 (en) | 2014-10-10 | 2023-02-01 | Idera Pharmaceuticals Inc | Cancer treatment using a tlr9 agonist with checkpoint inhibitors |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
EP3949984A1 (en) * | 2015-02-13 | 2022-02-09 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
ES2874558T3 (es) | 2015-03-04 | 2021-11-05 | Igm Biosciences Inc | Moléculas de unión a CD20 y usos de las mismas |
US20180256715A1 (en) * | 2015-05-13 | 2018-09-13 | The Board Of Regents Of The University Of Texas System | Anti-ctla-4 blockade |
EP3297660A2 (en) | 2015-05-20 | 2018-03-28 | The Broad Institute Inc. | Shared neoantigens |
MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
MA42459A (fr) | 2015-07-16 | 2018-05-23 | Bioxcel Therapeutics Inc | Nouvelle approche pour le traitement du cancer par immunomodulation |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
AU2016329197B2 (en) | 2015-09-30 | 2021-01-21 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
CN108463472A (zh) * | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
WO2017070110A1 (en) | 2015-10-19 | 2017-04-27 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
TWI717432B (zh) | 2015-12-02 | 2021-02-01 | 美商艾吉納斯公司 | 抗體和使用彼之方法 |
WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
AU2017217881B2 (en) | 2016-02-12 | 2022-11-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
CN108778301A (zh) | 2016-03-10 | 2018-11-09 | 永恒生物科技股份有限公司 | 通过联合疗法来治疗实体瘤或淋巴瘤的方法 |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
JP7137474B2 (ja) | 2016-03-15 | 2022-09-14 | メルサナ セラピューティクス,インコーポレイティド | NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法 |
EP3432926A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHODS OF REDUCING THE TOXICITY OF A CHEMOTHERAPEUTIC MEDICAMENT |
US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
WO2017205756A1 (en) * | 2016-05-27 | 2017-11-30 | The Board Of Regents Of The University Of Texas System | 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in therapy-resistant cancer cells |
SI3463436T1 (sl) | 2016-06-02 | 2024-02-29 | Ultimovacs Asa | Cepivo v kombinaciji z zaviralcem imunske kontrolne točke za uporabo pri zdravljenju raka |
RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
WO2018045239A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Carrier-pd-l1 binding agent compositions for treating cancers |
CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
KR20230010817A (ko) | 2016-09-06 | 2023-01-19 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법 |
EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
CA3035655A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
SG10201912560YA (en) | 2016-12-07 | 2020-02-27 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
WO2018120842A1 (zh) | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
WO2018160538A1 (en) | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
BR112019017695A2 (pt) | 2017-02-28 | 2020-04-07 | Bristol-Myers Squibb Company | uso de anticorpos anti-ctla-4 com adcc acentuada para acentuar a resposta imune a uma vacina |
WO2018191654A1 (en) | 2017-04-14 | 2018-10-18 | Cold Genesys, Inc. | Methods of treating bladder cancer |
AU2017414149A1 (en) | 2017-05-19 | 2019-11-07 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
WO2018226336A1 (en) | 2017-06-09 | 2018-12-13 | Providence Health & Services - Oregon | Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer |
RU2020118134A (ru) * | 2017-11-03 | 2021-12-03 | Маккей Мемориал Хоспитал | Способ модуляции опухолеассоциированных миелоидных клеток и улучшения блокады иммунных контрольных точек |
EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
CN108003238B (zh) * | 2017-11-30 | 2021-02-02 | 常州费洛斯药业科技有限公司 | 一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途 |
EP3727463A1 (en) | 2017-12-21 | 2020-10-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
CA3125731A1 (en) | 2018-01-12 | 2019-07-18 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
MA53651A (fr) | 2018-09-19 | 2021-07-28 | Alpine Immune Sciences Inc | Méthodes et utilisations de protéines de fusion de variant cd80 et constructions associées |
US20230021500A1 (en) | 2018-10-29 | 2023-01-26 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
WO2020236253A1 (en) | 2019-05-20 | 2020-11-26 | Massachusetts Institute Of Technology | Boronic ester prodrugs and uses thereof |
EP3878446A1 (en) | 2020-03-09 | 2021-09-15 | Universite De Geneve | Hsd11b1 inhibitors for use in immunotherapy and uses thereof |
US20210335467A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2024089418A1 (en) | 2022-10-24 | 2024-05-02 | Cancer Research Technology Limited | Tumour sensitisation to checkpoint inhibitors with redox status modifier |
WO2024089417A1 (en) | 2022-10-24 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | Tumour stratification for responsiveness to an immune checkpoint inhibitor |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4681581A (en) * | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4740461A (en) * | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US5101827A (en) * | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4735210A (en) * | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) * | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) * | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
DE3708238A1 (de) * | 1987-03-16 | 1988-09-29 | Motoren Werke Mannheim Ag | Kraft-waerme-kopplungsanlage |
US5750172A (en) * | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5648471A (en) * | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5151510A (en) * | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2090473A1 (en) * | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
AU661854B2 (en) | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
WO1993016043A1 (en) * | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5556763A (en) * | 1992-04-06 | 1996-09-17 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Evaluation and treatment of patients with progressive immunosuppression |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
PT804070E (pt) * | 1993-03-09 | 2000-11-30 | Genzyme Corp | Isolamento de componentes de interesse a partir do leite. |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
EP0703979B1 (en) | 1993-06-04 | 2000-09-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method for treating kaposi's sarcoma with antisense oligonucleotides |
CA2144319A1 (en) | 1993-07-09 | 1995-01-19 | George N. Cox | Recombinant ctla4 polypeptides and methods for making the same |
WO1995003408A1 (en) | 1993-07-26 | 1995-02-02 | Dana-Farber Cancer Institute | B7-2: ctl a4/cd 28 counter receptor |
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5759546A (en) * | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
ATE197766T1 (de) | 1994-03-08 | 2000-12-15 | Dana Farber Cancer Inst Inc | VERFAHREN ZUR MODULATION VON ßT-ZELL-ANERGYß |
US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
EP0804604A2 (en) | 1995-01-20 | 1997-11-05 | Cell Genesys, Inc. | Method to improve screening efficiency in fused cells |
US5703057A (en) * | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
EP0773288A3 (en) | 1995-08-29 | 1997-07-09 | Kirin Brewery | Chimera animal and its method of manufacture |
US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
DK0942968T3 (da) | 1996-12-03 | 2008-06-23 | Amgen Fremont Inc | Fuldt humane antistoffer, der binder EGFR |
US20060034844A1 (en) * | 1996-12-04 | 2006-02-16 | The Regents Of The University Of California | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
DE69835145T2 (de) | 1997-02-28 | 2007-06-14 | Kirin Beer K.K. | Transgene Mäuse die ein menschliches Antikörper exprimieren |
WO1998042752A1 (en) * | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
CA2205680A1 (en) | 1997-05-16 | 1998-11-16 | The University Of Western Ontario | Clip immunomodulatory peptide |
CA2241621A1 (en) | 1998-06-26 | 1999-12-26 | National Silicates Ltd. | A lubricating method for silicate drilling fluids |
DE69942037D1 (de) * | 1998-12-23 | 2010-04-01 | Amgen Fremont Inc | Humane monoklonale antikörper gegen ctla-4 |
US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
WO2002012272A2 (en) * | 2000-08-04 | 2002-02-14 | Genzyme Corporation | Therapeutic anti-melanoma compounds |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
US20030175250A1 (en) * | 2002-02-13 | 2003-09-18 | Elke Jager | Isolated peptides which bind to HLA molecules and uses thereof |
EP1503794B9 (en) * | 2002-04-12 | 2012-09-19 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
US7465446B2 (en) * | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
US7410253B2 (en) * | 2004-05-13 | 2008-08-12 | Ic! Berlin Brillenproduktions Gmbh | Spectacles |
PT2161336E (pt) * | 2005-05-09 | 2013-10-03 | Ono Pharmaceutical Co | Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿ |
AU2006311475A1 (en) * | 2005-11-08 | 2007-05-18 | Medarex, Inc. | TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
NZ568016A (en) * | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
-
2003
- 2003-04-11 EP EP03728392A patent/EP1503794B9/en not_active Expired - Lifetime
- 2003-04-11 AU AU2003234736A patent/AU2003234736B2/en not_active Expired
- 2003-04-11 IL IL16428703A patent/IL164287A0/xx unknown
- 2003-04-11 ES ES03728392T patent/ES2384168T3/es not_active Expired - Lifetime
- 2003-04-11 DK DK03728392.6T patent/DK1503794T3/da active
- 2003-04-11 PT PT03728392T patent/PT1503794E/pt unknown
- 2003-04-11 US US10/411,973 patent/US7452535B2/en not_active Expired - Lifetime
- 2003-04-11 AT AT03728392T patent/ATE552849T1/de active
- 2003-04-11 CA CA2481207A patent/CA2481207C/en not_active Expired - Lifetime
- 2003-04-11 MX MXPA04010013A patent/MXPA04010013A/es active IP Right Grant
- 2003-04-11 CN CNA038108593A patent/CN1652820A/zh active Pending
- 2003-04-11 BR BR0309254-2A patent/BR0309254A/pt not_active Application Discontinuation
- 2003-04-11 SI SI200332167T patent/SI1503794T1/sl unknown
- 2003-04-11 WO PCT/US2003/011444 patent/WO2003086459A1/en active Application Filing
- 2003-04-11 JP JP2003583476A patent/JP2005529873A/ja active Pending
- 2003-04-11 NZ NZ536420A patent/NZ536420A/en not_active IP Right Cessation
-
2004
- 2004-09-26 IL IL164287A patent/IL164287A/en active IP Right Grant
- 2004-10-28 ZA ZA2004/08732A patent/ZA200408732B/en unknown
-
2008
- 2008-10-07 US US12/246,791 patent/US8142778B2/en not_active Expired - Fee Related
- 2008-12-09 AU AU2008255203A patent/AU2008255203B2/en not_active Expired
-
2012
- 2012-07-06 CY CY20121100606T patent/CY1113243T1/el unknown
- 2012-10-01 HU HUS1200022C patent/HUS1200022I1/hu unknown
Also Published As
Publication number | Publication date |
---|---|
SI1503794T1 (sl) | 2012-09-28 |
EP1503794A1 (en) | 2005-02-09 |
EP1503794A4 (en) | 2005-06-15 |
WO2003086459A1 (en) | 2003-10-23 |
US7452535B2 (en) | 2008-11-18 |
ZA200408732B (en) | 2005-09-28 |
US8142778B2 (en) | 2012-03-27 |
EP1503794B9 (en) | 2012-09-19 |
ES2384168T3 (es) | 2012-07-02 |
CN1652820A (zh) | 2005-08-10 |
HUS1200022I1 (hu) | 2012-11-28 |
US20040005318A1 (en) | 2004-01-08 |
CA2481207A1 (en) | 2003-10-23 |
NZ536420A (en) | 2008-04-30 |
US20090117037A1 (en) | 2009-05-07 |
CA2481207C (en) | 2015-06-30 |
MXPA04010013A (es) | 2004-12-13 |
PT1503794E (pt) | 2012-06-21 |
ES2384168T9 (es) | 2013-01-16 |
AU2003234736A1 (en) | 2003-10-27 |
JP2005529873A (ja) | 2005-10-06 |
AU2008255203A1 (en) | 2009-01-08 |
BR0309254A (pt) | 2005-03-01 |
DK1503794T3 (da) | 2012-07-23 |
EP1503794B1 (en) | 2012-04-11 |
AU2003234736B2 (en) | 2008-09-25 |
IL164287A0 (en) | 2005-12-18 |
IL164287A (en) | 2013-07-31 |
AU2008255203B2 (en) | 2011-03-10 |
ATE552849T1 (de) | 2012-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113243T1 (el) | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 | |
CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
CY1123535T1 (el) | Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας | |
CY1110530T1 (el) | Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων | |
CY1121254T1 (el) | Συνθεσεις αντισωματων anti-ctla-4 | |
CY1122346T1 (el) | Μονοκλωνα αντισωματα εναντι tης κλαουδινης 18 για τη θεραπεια του καρκινου | |
CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
CY1110759T1 (el) | Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων | |
CY1106357T1 (el) | Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
CY1115745T1 (el) | Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου | |
LTPA2016028I1 (lt) | Imunoglobulino chimeriniai monomero-dimero hibridai | |
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
CY1108387T1 (el) | Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18 | |
CY1111237T1 (el) | Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης | |
BR0314814A (pt) | Variantes otimizadas de fc e métodos para sua geração | |
HUP0402029A2 (hu) | Peptidalapú multimer célzott kontrasztanyagok | |
CY1110571T1 (el) | Επιλεκτικα μεσα δεσμευσης της ανθρωπινης αγγειοποιητινης-2 | |
CY1109525T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
BRPI0411854A (pt) | veìculos protéicos para vacinas | |
DK1572087T3 (da) | Antistoffer med cancerantigen TMEFF2 og anvendelser deraf | |
WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
CY1113789T1 (el) | Συνδυασμοι απο ενεργοποιητες διαυλων καλιου και αναστολεις διαυλων νατριου ή δραστικες ουσιες που επηρεαζουν τους διαυλους νατριου για τη θεραπεια επωδυνων καταστασεων | |
CY1105980T1 (el) | Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου |